COVID-19 is responsible for a worldwide pandemic, with a high rate of morbidity and mortality. The increasing evidence of an associated relevant pro-thrombotic coagulopathy has resulted in an increasing use of antithrombotic doses higher than usual in COVID-19 patients. Information on the benefit/risk ratio of this approach is still lacking.
The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience
Pesavento, Raffaele;Ceccato, Davide;Frigo, Anna chiara;Gorgi, Davide;Postal, Anna;Cipriani, Alberto;Criveller, Pietro;Gemelli, Marco;Capone, Federico;Fioretto, Paola;Pagano, Claudio;Rossato, Marco;Avogaro, Angelo;Simioni, Paolo;Prandoni, Paolo;Vettor, Roberto
2020
Abstract
COVID-19 is responsible for a worldwide pandemic, with a high rate of morbidity and mortality. The increasing evidence of an associated relevant pro-thrombotic coagulopathy has resulted in an increasing use of antithrombotic doses higher than usual in COVID-19 patients. Information on the benefit/risk ratio of this approach is still lacking.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
